Looking Ahead: The Future of Chronic GVHD Management and Patient Care

Opinion
Video

Panelists conclude by discussing the future of graft-versus-host disease management, expressing their hopes for the current treatment landscape and potential advancements that could further improve patient outcomes and quality of life.

Video content above is prompted by the following:

Can you tell us about axatilimab and its potential role in cGVHD treatment? How does its mechanism of action differ from other therapies? Please briefly highlight the AGAVE-201 trial and data.

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
diverse hands being raised

How to Overcome 4 Common Barriers to Cancer Clinical Trial Access

Brielle Benyon
November 7th 2024
Article

An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and what clinicians can do to mitigate these disparities.

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

Darlene Dobkowski, MA
August 14th 2024
Article

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Chris Ryan
August 11th 2024
Article

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

Roman Fabbricatore
July 30th 2024
Article

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

Responses to Belumosudil Persist at 3 Years in Chronic GVHD

Responses to Belumosudil Persist at 3 Years in Chronic GVHD

Ashling Wahner
May 7th 2024
Article

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

Darlene Dobkowski, MA
April 26th 2024
Article

A feasibility study on the use of a mobile application for patients after undergoing a stem cell transplant may help care teams quickly identify and treat graft-versus-host disease.

© 2024 MJH Life Sciences

All rights reserved.